Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC

Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study

“…In terms of response to systemic chemotherapy, several previous studies have also indicated that TTF-1-negative NSCLC exhibits a less favorable therapeutic response with pemetrexed-based chemotherapy than TTF-1-positive NSCLC ( 7 , 15 , 16 ). Recent studies have reported that this result also holds true for chemoimmunotherapy ( 9 , 10 , 17 – 20 ). Actually, our previous study similarly reported a significantly lower therapeutic response to chemoimmunotherapy in the TTF-1-negative population compared to the TTF-1-positive population ( 11 ).…”

“…TTF-1 expression has been reported as a potential prognostic factor in patients with NSCLC and has also been previously reported to be significantly associated with therapeutic response to cytotoxic anticancer agents, particularly pemetrexed, with favorable results in TTF-1 positive patients ( 7 , 8 ). Similarly, several reports on immunotherapy alone or chemoimmunotherapy have indicated that TTF-1-positive non-squamous NSCLC patients tend to have a better therapeutic response ( 9 – 11 ). However, there has been no evaluation of the impact of TTF-1 expression on the therapeutic effect of immunotherapy alone or chemotherapy in patients with NSCLC with high PD-L1 expression who are strongly affected by immunotherapy.…”